Shay Yeganeh

Poriyya `illit, Z 15208, Israel

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Central retinal vein occlusion in a young patient following hookah smoking.

Central retinal vein occlusion in a young patient following hookah smoking.

Journal: Journal francais d'ophtalmologie

Published: November 12, 2022

Clinical features, therapy patterns, outcomes and prognostic factors of solitary plasmacytomas: a report of the Israeli Myeloma Study Group.

Clinical features, therapy patterns, outcomes and prognostic factors of solitary plasmacytomas: a report of the Israeli Myeloma Study Group.

Journal: Leukemia & lymphoma

Published: September 08, 2022

COVID-19 among patients with hematological malignancies: a national Israeli retrospective analysis with special emphasis on treatment and outcome.

COVID-19 among patients with hematological malignancies: a national Israeli retrospective analysis with special emphasis on treatment and outcome.

Journal: Leukemia & lymphoma

Published: August 18, 2021

Venetoclax is safe and efficacious in relapsed/refractory AML.

Venetoclax is safe and efficacious in relapsed/refractory AML.

Journal: Leukemia & lymphoma

Published: May 19, 2020

Primary autoimmune myelofibrosis: A case report in a child.

Primary autoimmune myelofibrosis: A case report in a child.

Journal: EJHaem

Published: May 04, 2020

BST-236, a novel cytarabine prodrug for patients with acute leukemia unfit for standard induction: a phase 1/2a study.

BST-236, a novel cytarabine prodrug for patients with acute leukemia unfit for standard induction: a phase 1/2a study.

Journal: Blood advances

Published: May 20, 2019

An alerting sign: Enlarged cardiac silhouette.

An alerting sign: Enlarged cardiac silhouette.

Journal: Cleveland Clinic journal of medicine

Published: December 15, 2015

Outcomes of light-chain amyloidosis patients treated with first-line bortezomib: a collaborative retrospective multicenter assessment.

Outcomes of light-chain amyloidosis patients treated with first-line bortezomib: a collaborative retrospective multicenter assessment.

Journal: European journal of haematology

Published: March 27, 2015

Higher infection rate after 7- compared with 5-day cycle of azacitidine in patients with higher-risk myelodysplastic syndrome.

Higher infection rate after 7- compared with 5-day cycle of azacitidine in patients with higher-risk myelodysplastic syndrome.

Journal: Clinical lymphoma, myeloma & leukemia

Published: October 14, 2014

Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: a retrospective multicenter study.

Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: a retrospective multicenter study.

Journal: American journal of hematology

Published: November 13, 2012

Showing 1-10 of 10

Last Updated: 09/26/2026